56. The use of intravenous immunoglobulin for dermatological disorders (Englisch)
- Neue Suche nach: Sticherling, M.
- Neue Suche nach: Sticherling, M.
- Neue Suche nach: Dalakas, M. C.
- Neue Suche nach: Spath, P. J.
In:
International symposium on the use of intravenous immunoglobulin (IVIG)
;
383-388
;
2004
-
ISBN:
- Aufsatz (Konferenz) / Print
-
Titel:56. The use of intravenous immunoglobulin for dermatological disorders
-
Beteiligte:
-
Kongress:5th, International symposium on the use of intravenous immunoglobulin (IVIG) ; 2003 ; Interlaken, Switzerland
-
Erschienen in:
-
Verlag:
- Neue Suche nach: Parthenon,
-
Erscheinungsort:Boca Raton , London:
-
Erscheinungsdatum:01.01.2004
-
Format / Umfang:6 pages
-
Anmerkungen:Includes bibliographical references and index
-
ISBN:
-
Medientyp:Aufsatz (Konferenz)
-
Format:Print
-
Sprache:Englisch
-
Schlagwörter:
-
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis Konferenzband
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 3
-
1. Manufacturing of intravenous immunoglobulin: challenges, achievements and opportunitiesMorell, A. et al. | 2004
- 9
-
2. Challenges and achievements in pathogen safety of intravenous immunoglobulinSpath, P. J. / Kempf, C. et al. | 2004
- 21
-
3. Treatment modalities and clinical efficacy of immunoglobulin G replacement therapies in primary immunodeficiencyWebster, A. D. B. et al. | 2004
- 29
-
4. Immunomodulation by intravenous immunoglobulin: idiopathic thrombocytopenic purpura as a modelImbach, P. et al. | 2004
- 37
-
5. Witnessing the introduction and use of intravenous immunoglobulin in neurologyDalakas, M. C. et al. | 2004
- 41
-
6. Pharmacoeconomics of intravenous immunoglobulin administration in neurological disorders: the US experienceDonofrio, P. D. et al. | 2004
- 47
-
7. Pharmacoeconomics of intravenous immunoglobulin for polyneuropathiesMcCrone, P. et al. | 2004
- 53
-
8. B-cell maturation to produce high-affinity antibodies of different isotypes and its abnormalitiesDurandy, A. et al. | 2004
- 57
-
9. The molecular basis of primary immune deficiency diseasesOchs, H. D. / Torgerson, T. R. / Lee, W.-I. / Jin, Y. Z. / Gambineri, E. / Zhu, Q. et al. | 2004
- 71
-
10. Safety in intravenous immunoglobulin therapyGelfand, E. W. et al. | 2004
- 77
-
11. Immunoglobulin replacement by the subcutaneous route using preparations licensed in the USA for administration by other routesBerger, M. / Duff, K. / Poll, J. / Roy, S. et al. | 2004
- 81
-
12. The use of intravenous immunoglobulin for allogeneic stem cell transplantation: the US experienceBuckley, R. H. et al. | 2004
- 85
-
13. Intravenous immunoglobulin for bone marrow/stem cell transplantation: the European experienceTheunissen, K. / Maertens, J. A. / Boogaerts, M. A. et al. | 2004
- 91
-
14. Secondary antibody deficiency following treatment of vasculitis: the use of intravenous immunoglobulinTormey, V. J. / Burns, A. et al. | 2004
- 95
-
15. Intravenous immunoglobulin in the prevention and treatment of severe infectionsWerdan, K. et al. | 2004
- 105
-
16. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseasesKazatchkine, M. D. / Bayry, J. / Lacroix-Desmazes, S. / Kaveri, S. V. et al. | 2004
- 113
-
17. Role of intravenous immunoglobulin in reversing glucocorticoid insensitivity or resistanceGelfand, E. W. et al. | 2004
- 121
-
18. Modulating the balance of activating and inhibiting Fcgamma receptors: mechanism of intravenous immunoglobulin actionPricop, L. et al. | 2004
- 127
-
19. Anti-inflammatory effects of intravenous immunoglobulin: Fcgamma receptor inhibition/blockade and non-Fcgamma receptor-mediated mechanismsSemple, J. W. / Lazarus, A. H. et al. | 2004
- 133
-
20. Immune modulation by intravenous immunoglobulin: some remarks on the role of Fc receptorsvan Mirre, E. / Hack, C. E. et al. | 2004
- 137
-
21. Intravenous immunoglobulin in reactive hemophagocytic syndrome: a paradigm of Fcgamma receptor and cytokine modulationMouthon, L. et al. | 2004
- 143
-
22. Anti-inflammatory effects of intravenous immunoglobulin through modulation of complement activitiesLutz, H. U. / Spath, P. J. et al. | 2004
- 149
-
23. Changes in gene expression profile in the muscles of patients with dermatomyositis and inclusion body myositis after therapy with intravenous immunoglobulin: a microarray analysis correlating gene expression with clinical outcomeRaju, R. / Dalakas, M. C. et al. | 2004
- 153
-
24. In vitro studies of mechanisms of action of intravenous immunoglobulin in Guillain-Barre syndrome and Miller-Fisher syndrome: a reviewGold, R. / Weishaupt, A. / Stangel, M. / Chan, A. / Toyka, K. V. et al. | 2004
- 161
-
25. The immunological rationale for intravenous immunoglobulin in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathyPollard, J. D. et al. | 2004
- 171
-
26. Intravenous immunoglobulin for Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy in adult patientsvan Doorn, P. A. et al. | 2004
- 181
-
27. Clinical experience with intravenous immunoglobulin for treatment of pediatric Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathyKornberg, A. J. et al. | 2004
- 187
-
28. Intravenous immunoglobulin for multifocal motor neuropathyvan den Berg, L. H. et al. | 2004
- 191
-
29. Intravenous immunoglobulins in paraproteinemic demyelinating neuropathiesLeger, J.-M. et al. | 2004
- 197
-
30. Immunoglobulins in IgM antimyelin-associated glycoprotein and other paraproteinemic neuropathiesComi, G. et al. | 2004
- 203
-
31. Intravenous immunoglobulin for myasthenia gravisGajdos, P. et al. | 2004
- 207
-
32. Intravenous immunoglobulin in polymyositis and dermatomyositisCherin, P. et al. | 2004
- 213
-
33. Controlled studies with high-dose intravenous immunoglobulin in the treatment of inclusion body myositisDalakas, M. C. et al. | 2004
- 221
-
34. Immune mechanisms and treatment perspectives in multiple sclerosisHohlfeld, R. et al. | 2004
- 229
-
35. A review of controlled clinical trials of intravenous immunoglobulin in multiple sclerosisSorensen, P. S. et al. | 2004
- 235
-
36. Intravenous immunoglobulin treatment for patients with primary or secondary progressive multiple sclerosisPohlau, D. / Kallweit, U. et al. | 2004
- 243
-
37. What is the effective dose of intravenous immunoglobulin for treatment of relapsing-remitting multiple sclerosis?Lewanska, M. / Siger-Zajdel, M. / Selmaj, K. et al. | 2004
- 257
-
38. High-dose intravenous immunoglobulin in the treatment of patients with stiff person syndrome: a controlled studyDalakas, M. C. et al. | 2004
- 267
-
39. Intravenous immunoglobulin in acute disseminated encephalomyelitisMarchioni, E. / Ravaglia, S. / Todeschini, A. / Pichiecchio, A. / Uggetti, C. / Piccolo, G. / Ceroni, M. et al. | 2004
- 279
-
40. Intravenous immunoglobulin in dermatologyJolles, S. et al. | 2004
- 283
-
41. The use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseasesAhmed, A. R. et al. | 2004
- 291
-
42. Treatment of atopic dermatitis, urticaria and psoriasis with intravenous immunoglobulinRustin, M. et al. | 2004
- 297
-
43. Intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndromeFrench, L. E. et al. | 2004
- 301
-
44. Intravenous immunoglobulin in the treatment of vasculitisJayne, D. et al. | 2004
- 313
-
45. Immunomodulation by intravenous immunoglobulin of alloantibodies to human leukocyte antigen: clinical aspects in solid organ transplantationGlotz, D. / Antoine, C. / Julia, P. / Pegaz-Fiornet, B. / Duboust, A. / Boudjeltia, S. / Fraoui, R. / Combes, M. / Bariety, J. et al. | 2004
- 321
-
46. Role of intravenous immunoglobulin in the management of heart failureKrum, H. et al. | 2004
- 331
-
47. Intravenous immunoglobulin: potential role in the management of severe acute respiratory syndromeChng, H. H. / Leong, K. P. / Leung, B. / Ang, B. / Leo, Y. S. / Loo, S. / Goh, S. K. / Lew, T. W. K. / Hsu, L. Y. / Arul, E. et al. | 2004
- 337
-
48. Enhancement of the immune response to Mycobacterium tuberculosis by high-dose intravenous immunoglobulin in miceJolles, S. / Roy, E. / Stavropoulos, V. / Coade, S. / Grigorieva, E. / Tascon, R. / Lowrie, D. et al. | 2004
- 343
-
49. Intravenous immunoglobulin for treatment of recurrent miscarriageNoens, L. A. E. et al. | 2004
- 349
-
50. Epilepsy and the immune system: is there a link?Lagae, L. G. et al. | 2004
- 357
-
51. Intravenous immunoglobulin as an immunomodulatory agent in systemic lupus erythematosus and lupus nephritisSherer, Y. / Shoenfeld, Y. et al. | 2004
- 361
-
52. Intravenous immunoglobulin for fibrosis, atherosclerosis and malignant conditionsKrause, I. / Shoenfeld, Y. et al. | 2004
- 369
-
53. Intravenous immunoglobulin for immune deficiencies and passive immunizationQuinti, I. / Cagliuso, M. / Aiuti, F. et al. | 2004
- 373
-
54. The use of intravenous immunoglobulin in hematology and transplantationProvan, D. et al. | 2004
- 377
-
55. The use of intravenous immunoglobulin in neurologyEngel, W. K. et al. | 2004
- 383
-
56. The use of intravenous immunoglobulin for dermatological disordersSticherling, M. et al. | 2004
- 389
-
57. The use of intravenous immunoglobulin in collagen vascular and heart diseasesLazarus, A. H. et al. | 2004
- 393
-
58. Intravenous immunoglobulin: mechanisms of actionWilliams, P. E. et al. | 2004
- 399
-
59. Pathogen safety and tolerability of intravenous immunoglobulinRossi, F. et al. | 2004
- 405
-
60. Pharmacoeconomics and evidence-based medicineAntonini, G. / Di Pasquale, A. et al. | 2004